Introduction {#Sec1}
============

The follicular cells of the thyroid gland constitutively express a homolog of the phagosomal NADPH oxidase, called dual oxidase 2 (DUOX2) that generates hydrogen peroxide at the apical membrane. By driving thyroid-peroxidase catalyzed iodide organification, this activity is rate limiting for the synthesis of thyroid hormone^[@CR1]^. In fact, mutations in *DUOX2*, first described in 2002^[@CR2]^, are now regarded the most common known genetic risk factor in congenital hypothyroidism (CH)^[@CR3]--[@CR7]^ found in up to 83% of CH cohorts^[@CR8]^. The severity of *DUOX2*-associated CH can range from transient neonatal hyperthyrotropinema to permanent profound hypothyroidism.

In addition to being constitutively expressed in thyrocytes, *DUOX2* is robustly induced in the barrier epithelial cells of the gastrointestinal tract as a sentinel response to potential microbial threats. *DUOX2* and its essential heterodimerization partner *DUOXA2* are part of a "*DUOX2* co-expression signature" most responsive to mucosal bacterial dysbiosis^[@CR9]^ and mice with a defect in the DUOX2 system were found to have increased intestinal bacterial translocation to both commensals and pathogenic bacteria consistent with a role of DUOX2 in supporting immune homeostasis^[@CR10]^, potentially by suppressing bacterial virulence^[@CR11]^. By its function and regulation, *DUOX2* is a candidate gene for inflammatory bowel diseases (IBD), chronic inflammatory disorders of the gastrointestinal tract. The most common forms of IBD are ulcerative colitis (UC), which is limited to colonic involvement, and Crohn's disease (CD), which can involve the entire length of the intestine. The current understanding of IBD pathogenesis is that an altered luminal microbial composition with epithelial dysfunction results in increased bacterial translocation and immune stimulation^[@CR12]^. Although no traditional pathogens are generally detected during active disease flares, increased virulence of commensal bacterial species, particularly *Escherichia coli*, can enhance their mucosal attachment, invasion, and intracellular persistence, leading to increased pathogen-recognition and mucosal inflammation^[@CR12]^. Although there is no information from the published literature that any of the previously reported CH patients with *DUOX2* mutations had GI symptoms, anecdotal support for the potential role of DUOX2 in IBD pathogenesis has been recently provided by reports of *DUOX2* loss-of-function mutations in children with IBD but not CH^[@CR13]--[@CR15]^. However, *DUOX2* lacks common allelic variants suitable for genome-wide association studies and whether *DUOX2* variants have an impact on IBD risk in the general population is unknown.

Since a high proportion of patients identified in neonatal CH screening programs harbor *DUOX2* variants that may also contribute to the susceptibility for IBD, we hypothesized that the prevalence of IBD would be increased for a CH cohort compared to a matched non-CH cohort. To test this hypothesis, we performed a retrospective cohort analysis using a national payer database in the United States comprising individual-level health care claims data for 230 million individuals.

Results {#Sec2}
=======

Patient demographics {#Sec3}
--------------------

Using the Truven Health MarketScan databases from 2009--2015, we identified 42,922 patients with CH and 42,922 age-and-gender matched non-CH individuals over the study period (Fig. [1](#Fig1){ref-type="fig"}). The mean (±standard deviation) age was 39.1 (25.5) years in each group. The percentage of females was 67.4% in either group. Additional baseline characteristics of patients are provided in Supplemental Table [1](#MOESM1){ref-type="media"}.Figure 1A diagram of the study cohort selection. CH = congenital hypothyroidism, IBD = inflammatory bowel disease, UC = ulcerative colitis, CD = Crohn's disease.

Increased prevalence of IBD in subjects with congenital hypothyroidism {#Sec4}
----------------------------------------------------------------------

To determine whether individuals with CH are at increased risk of developing IBD, we compared the prevalence of IBD in CH vs. non-CH cohorts (n = 42,922). A significantly higher prevalence of patients having any IBD subtype was found in CH vs. non-CH cohorts (p \< 0.0001, Table [1](#Tab1){ref-type="table"}). The estimated prevalence of IBD per 100,000 individuals is 520 in CH and 300 in non-CH, indicating a 73% increased risk for developing IBD in CH patients. The higher prevalence was primarily due to increased risk for indeterminate colitis or UC, with only a trend towards more frequent occurrence of CD (Table [1](#Tab1){ref-type="table"}). We found no significant difference in IBD severity based on the rate of hospitalization and IBD flare (data not shown).Table 1The prevalence of IBD in patients with CH vs. non-CH controls.CH N = 42,922non-CH N = 42,922p valueCD63 (0.15%)51 (0.12%)0.2607UC91 (0.21%)54 (0.13%)\<0.0021Indeterminate Colitis68 (0.16%)22 (0.05%)\<0.0001Any IBD222 (0.52%)127 (0.30%)\<0.0001

Sensitivity Analyses {#Sec5}
--------------------

To apply a stricter definition of CH, we applied a 3 ICD code requirement for CH and found similar results of an increased prevalence of any IBD in those with CH compared to those with no CH (0.52% vs. 0.28%; p \< 0.0001) and stronger association with indeterminate colitis and UC (Supplemental Table [2](#MOESM1){ref-type="media"}).

Transient CH patients have the highest risk of developing IBD {#Sec6}
-------------------------------------------------------------

Children with CH that regain normal thyroid function during early life are classified as transient CH. Whereas permanent CH is caused by a variety of genetic defects in addition to *DUOX2* (e.g., *TPO*, *TG*, *PAX8*) as well as sporadic developmental abnormalities (e.g., ectopic thyroid gland), partial defects in the DUOX2 enzyme complex (*DUOX2*, *DUOXA2*) are the major known genetic risk factor for transient CH^[@CR1],[@CR2],[@CR16]--[@CR18]^. Compared to a cohort of patients with permanent CH, one limited to transient CH cases is likely enriched for *DUOX2* defects. Thus, if the excess risk for IBD in CH patients is due to higher *DUOX2* mutational load, IBD risk is anticipated to be even higher in transient CH (operationally defined as individuals diagnosed with CH not taking levothyroxine (T4) during the observation period) vs permanent CH (defined as those taking T4). Only patients in the CH cohort who had available pharmacy records were included in these analyses. Both permanent and transient CH cohorts had increased prevalence of IBD compared to non-CH controls (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}), but the odds ratio was significantly higher for transient CH patients (OR 2.39 (95% CI 1.77--3.23) vs 1.69 (95% CI 1.31--2.18), respectively, Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}**)**. Compared to permanent CH patients, the prevalence of IBD in the transient CH group was 72% higher (0.81% vs 0.47%; p = 0.0003; non-CH: 0.30%) (Table [6](#Tab6){ref-type="table"}). Similar to the findings for the total CH cohort, the strength of association between transient CH and IBD was highest for indeterminate colitis, followed by UC, and appeared to be weakest for CD.Table 2The prevalence of IBD in patients with permanent CH (i.e., taking T4) vs. patients without CH (Bivariate comparison).Permanent CH N = 24,306Non-CH N = 42,922p valueCD33 (0.14%)51 (0.12%)0.5501UC47 (0.19%)54 (0.13%)0.0298Indeterminate Colitis34 (0.14%)22 (0.05%)0.0001Any IBD114 (0.47%)127 (0.30%)0.0003Table 3The prevalence of IBD in patients with transient CH (i.e., [not]{.ul} taking T4) vs. patients without CH (Bivariate comparison).Transient CH N = 8,128Non-CH N = 42,922p valueCD21 (0. 26%)51 (0.12%)0.0021UC28 (0. 34%)54 (0.13%)\<0.0001Indeterminate Colitis17 (0. 21%)22 (0.05%)\<0.0001Any IBD66 (0. 81%)127 (0.30%)\<0.0001Table 4The primary endpoint (diagnosis of IBD) in patients with permanent CH vs. non-CH cohort (Multivariable Logistic Regression Models) - summarized models.Model\*Dependent variableOdds Ratio\*\*95% Confidence intervalp-value1UC1.641.11--2.430.01362Indeterminate Colitis2.901.23--2.380.00013Any IBD1.691.31--2.18\<0.0001\*All three models adjusted for age and gender (see Supplemental Table [4](#MOESM1){ref-type="media"} for the complete models).\*\*The odds of developing an endpoint in patients with CH taking T4 vs non-CH patients.Table 5The primary endpoint (diagnosis of IBD) in patients with transient CH vs. non-CH cohort (Multivariable Logistic Regression Models) - summarized models.Model\*Dependent variableOdds Ratio\*\*95% Confidence intervalp-value1CD1.771.06--2.960.02912UC2.481.56--3.940.00013Indeterminate Colitis3.641.91--6.91\<0.00014Any IBD2.391.77--3.23\<0.0001\*All four models adjusted for age and gender (see Supplemental Table [5](#MOESM1){ref-type="media"} for the complete models).\*\*The odds of developing an endpoint in patients with CH not taking T4 vs. non CH patients.Table 6IBD prevalence in patients with transient CH ([not]{.ul} taking T4) vs. permanent CH (taking T4).Transient CH N = 8,128Permanent CH N = 24,306p valueCD21 (0.26%)33 (0.14%)0.0189UC34 (0.28%)47 (0.19%)0.0141Indeterminate Colitis22 (0.21%)34 (0.14%)0.1724Any IBD66 (0.81%)114 (0.47%)0.0003

Discussion {#Sec7}
==========

In a large cohort of the commercially insured U.S. population, we found an increased prevalence of IBD among individuals with CH compared to those without CH. To our knowledge, this is the first study providing evidence for the existence of a common risk factor for these conditions.

Hypothyroidism, more broadly defined and including common acquired causes, has previously been studied in IBD patients, and its frequency was either found to be unchanged or even lower than in non-IBD controls^[@CR19]^. Thus hypothyroidism does not appear to be a risk factor in the pathogenesis of IBD. Rather, a suggestive link between IBD and hyperthyroidism, commonly due to autoimmune thyroid disorders, has been found in some studies^[@CR20]^. This is potentially due to a shared immune pathology, which can lead to increased inflammation of distinct target organs. In light of these prior studies, the clear association between IBD risk and CH in the U.S. population reported here is notable and would indeed support the concept of a shared inborn susceptibility event, such as, variants in the *DUOX2* system that are relevant for thyroid function as well as intestinal immune homeostasis. Interestingly, the association between CH and IBD risk was not related to the severity of CH but was higher for individuals with transient CH. Among the 32,434 CH cohort with available pharmacy claims data, 8,128 (25%) were apparently not treated with T4 and operationally defined as transient CH cases (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [6](#Tab6){ref-type="table"}). Although these may include individuals with mild permanent CH in whom treatment had been inappropriately discontinued, the high prevalence of CH cases without ongoing T4 treatment is consistent with an earlier study estimating that by 36 months of age, 38% of US children diagnosed with CH had discontinued T4 treatment^[@CR21]^. Common genetic defects that frequently manifest as transient-only CH are partial defects in the genes encoding the subunits of the rate-limiting enzyme in thyroid hormone synthesis, *DUOX2* and *DUOXA2*^[@CR1],[@CR2],[@CR16],[@CR17]^.

*DUOX2* loss-of-function variants appear to be the most common genetic abnormality in CH patients^[@CR3]--[@CR7]^. Since DUOX2 is rate-limiting for hormone synthesis, even mild heterozygous defects are anticipated to increase serum TSH level, which varies by one order of magnitude in the general population. However, minor defects are not necessarily sufficient to manifest haploinsufficiency detected by abnormal neonatal CH screening results. In fact, low genetic penetrance for CH is indicated by studies of families in which heterozygous mutation carriers other than the proband were consistently found to have normal thyroid function tests. Furthermore, by reviewing of *DUOX2* variants found in the general population (ExAC database)^[@CR22]^ we identified a wide spectrum of loss-of-function variants (Supplemental Table [3](#MOESM1){ref-type="media"}). While the frequency of individual variants is far below the threshold required for genome-wide association studies, the combined mutational load is substantial. For instance, over 3.2% of the general population harbor one of the previously *in vitro* tested loss-of-function variants (32 variants with *in vitro* activity ≤60% of the reference allele)^[@CR23]^ with an even higher proportion of individuals carrying uncharacterized, but predicted to be deleterious variants, considerably higher than the prevalence of even mild CH (Supplemental Table [3](#MOESM1){ref-type="media"}). Similarly, among East Asians, over 2% carry the Y246X *DUOXA2* complete loss-of-function allele, which has been linked to mild CH in the homozygous state^[@CR24]^.

Additional risk factors presumably relevant for precipitating disease in carriers of *DUOX2* mutations are distinct for CH and IBD. For CH, the function of the *DUOX1* isoenzyme is likely critical for the potential to compensate partial *DUOX2* defects^[@CR25]^ and expressivity of the defects is presumably modulated by nutritional iodine intake^[@CR1]^. Noteworthy, *DUOX1* is expressed in the thyroid epithelial cells but not in the intestine, so compensated partial *DUOX2* defects without associated CH might still have an impact on intestinal immune homeostasis leading to intestinal inflammation. For IBD, a different set of genetic (e.g., *NOD2*) and environmental (e.g., intestinal microbiota) factors are involved in its pathogenesis. It is thus not surprising that among the so-far studied pediatric CH cohorts with *DUOX2* mutations no case of concurrent IBD has been reported, and that the recently described cases of *DUOX2*-associated IBD all had apparently normal thyroid function parameters^[@CR13]--[@CR15]^. Based on the high frequency of *DUOX2* mutations in unselected CH cohorts of various ethnic origins^[@CR3]--[@CR7]^, our finding of a significantly increased risk of developing IBD among CH individuals lends support for the hypothesis of a shared susceptibility factor, specifically *DUOX2* genetic variants that can affect both thyroid function as well as intestinal immune homeostasis.

An obvious strength of the current study is the large sample size that made testing the main hypothesis feasible. However, several limitations must also be noted. First, there are general limitations of claims based data not collected for research purposes, such as data entry errors and underreporting of diagnoses. To ameliorate the influence of misdiagnoses, we used a 2--3 code requirement in this study. Second, although we matched the study cohorts by age and gender, a generally acceptable method, it is not possible to fully account and correct for other possible confounders (e.g., smoking status, ethnicity).

In summary, we demonstrated a significant association between CH and the development of IBD providing evidence for a shared susceptibility factor. The risk was highest for patients with transient CH, for which partial defects in the DUOX2 system are a frequent genetic cause. Thus our results would seem to support the hypothesis that *DUOX2* mutation carriers, common in the general population, are not only at increased risk for thyroid dysfunction but also impaired intestinal immune homeostasis.

Methods {#Sec8}
=======

Study Design and Data Source {#Sec9}
----------------------------

We performed a retrospective cohort analysis to compare the prevalence of IBD in patients with and without CH. We queried the Truven Health MarketScan databases from January 1^st^, 2009 through December 31^st^, 2015 to identify patients with CH and a matched cohort of patients without CH. The MarketScan databases contain health insurance claims for over 230 million privately insured patients in the U.S. This study was considered exempt by the Institutional review board at the University of Michigan due to the de-identified nature of the dataset.

Study sample {#Sec10}
------------

The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes were used to identify patients with CH (243.x) and IBD (555.x and 556.x). In order to ensure that CH was confirmed, patients were selected for inclusion if they had at least 2 of the CH ICD-9-CM code in an outpatient setting in 2 different visits while for IBD diagnosis, patients were selected if they had at least 3 ICD-9 codes of IBD in an outpatient setting in 3 different visits between 2009--2015. This approach has a positive predictive value for CD of 0.84 and a positive predictive value for UC of 0.91^[@CR26]^. We also required at least 1-year enrollment to adequately capture diagnoses and eliminate possible confounding resulting from loss of follow-up. Patients meeting the inclusion criteria for CH were matched in their birth year and sex, in a 1-to-1 fashion, to patients with no CH diagnosis selected from the pool of database participants. If a patient with CH had more than one match, a randomized algorithm was employed to select a match.

Primary Outcome {#Sec11}
---------------

The primary endpoint was a diagnosis of IBD in patients with and without CH at any point of the study period. Given the congenital nature of CH, it is safe to assume that IBD manifested after the diagnosis of CH.

Statistical Analysis {#Sec12}
--------------------

We compared the demographics and prevalence of IBD diagnosis between the two cohorts using the Chi-square test for categorical data, and the Student *t*-test and Mann Whitney U test for continuous data. In sensitivity analyses, we used multivariable logistic regression models to adjust for age and gender in subgroup analyses. Variables (e.g., gender and age groups) were selected for inclusion in the multivariable model if they were significant in bivariate analyses (Supplemental Tables [4](#MOESM1){ref-type="media"} and [5](#MOESM1){ref-type="media"}). A two-sided p \< 0.05 was used to denote statistical significance. All analyses were performed using Statistical Analysis System (SAS) software version 9.4 (SAS Institute, Inc., Cary, NC). The 1-to-1 matching was performed with R version 3.3.2 (R foundation, Vienna, Austria).
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